2023
Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma
Chow R, Long J, Hassan S, Wheeler S, Spees L, Leapman M, Hurwitz M, McManus H, Gross C, Dinan M. Disparities in immune and targeted therapy utilization for older US patients with metastatic renal cell carcinoma. JNCI Cancer Spectrum 2023, 7: pkad036. PMID: 37202354, PMCID: PMC10276895, DOI: 10.1093/jncics/pkad036.Peer-Reviewed Original ResearchConceptsOral anticancer agentsTherapy utilizationMedicare beneficiariesNon-Hispanic white raceMetastatic renal cell carcinomaNon-Hispanic black raceOlder US patientsUS Medicare beneficiariesRenal cell carcinomaLogistic regression modelsTherapy receiptMultivariable adjustmentSystemic therapyMale sexUS patientsCell carcinomaStudy criteriaBlack raceFemale sexPatient raceWhite raceImmunotherapyOutcomes persistSexPatients
2017
Risk factors for hospitalizations (HOS) among older adults with gastrointestinal (GI) cancers receiving chemotherapy.
Li D, Sun C, Levi A, Klepin H, Elias R, Mohile S, Tew W, Lim D, Chung V, Chao J, Owusu C, Muss H, Lichtman S, Gross C, Chapman A, Gajra A, Cohen H, Katheria V, Hurria A. Risk factors for hospitalizations (HOS) among older adults with gastrointestinal (GI) cancers receiving chemotherapy. Journal Of Clinical Oncology 2017, 35: e21523-e21523. DOI: 10.1200/jco.2017.35.15_suppl.e21523.Peer-Reviewed Original ResearchGI cancersRisk factorsCardiac comorbiditiesOlder adultsGeriatric assessmentOdds ratioLow serum albuminStage IV diseaseIncidence of hospitalizationRisk of hospitalizationAdults age 65Days post treatmentChemotherapy typePatient agePatient characteristicsProspective studyFemale sexGastrointestinal cancerChemotherapy treatmentUnivariate analysisLaboratory valuesHospitalizationChemotherapyMultivariate analysisPatients